Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. UCB
  6. Summary
    UCB   BE0003739530

UCB

(UCB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
90.32(c) 90.88(c) 90.2(c) 92.86(c) 92.3(c) Last
175 139 141 855 195 537 375 546 418 693 Volume
-0.96% +0.62% -0.75% +2.95% -0.60% Change
More quotes
Estimated financial data (e)
Sales 2021 5 633 M 6 605 M 6 605 M
Net income 2021 972 M 1 140 M 1 140 M
Net Debt 2021 836 M 980 M 980 M
P/E ratio 2021 17,6x
Yield 2021 1,42%
Sales 2022 5 299 M 6 213 M 6 213 M
Net income 2022 815 M 956 M 956 M
Net Debt 2022 196 M 230 M 230 M
P/E ratio 2022 20,7x
Yield 2022 1,46%
Capitalization 17 427 M 20 457 M 20 434 M
EV / Sales 2021 3,24x
EV / Sales 2022 3,33x
Nbr of Employees 7 600
Free-Float 59,1%
More Financials
Company
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone... 
Sector
Pharmaceuticals
Calendar
02/24Earnings Release
More about the company
Ratings of UCB
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about UCB
09/16ANALYST RECOMMENDATIONS : Activision Blizzard, Beyond Meat, Britvic, Las Vegas S..
09/13UCB : Our R&D Response to COVID-19, A Patients' First Approach
AQ
09/13UCB : Using our innovative antibody know-how to enhance the power …
PU
09/10UCB : Disposals of own shares
PU
09/10OUR R&D RESPONSE TO COVID-19 : A Patients' First Approach
PU
09/08UCB : The pursuit of continuous innovation
PU
09/07PRESS RELEASE : CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) ..
DJ
09/07CEVEC Pharmaceuticals GmbH and UCB SA Sign Agreement for the Use of CEVEC's E..
CI
09/06UCB : BIMZELX▼ (bimekizumab) Receives First Positive Health Technology Ass..
PU
09/03UCB : Disposals of own shares
PU
09/03UCB : Transparency notification Wellington
PU
09/03UCB'S BRAINE SITE : Biopharma's best-kept secret
AQ
09/02ANALYST RECOMMENDATIONS : AstraZeneca, Designer Brands, Homeserve, Rio Tinto, Tr..
09/01UCB : Meeting unmet needs in epilepsy management through digital health technolo..
PU
08/30UCB : Evolving the epilepsy treatment paradigm
AQ
More news
News in other languages on UCB
09/16BRUSSELS STOCK EXCHANGE : UCB uitblinker op groene beurs
09/16UCB : Jefferies relève sa recommandation à l'achat
09/16UCB : en tête du BEL, Jefferies passe à l'achat
09/16Brussel blijft in het groen
09/16AVIS D'ANALYSTES DU JOUR : Air France KLM, Eurofins, Infineon, Idorsia, Ab Inbev..
More news
Analyst Recommendations on UCB
More recommendations
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | MarketScreener
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 92,30 €
Average target price 114,10 €
Spread / Average Target 23,6%
EPS Revisions
Managers and Directors
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Sandrine Dufour Chief Financial Officer & Executive Vice President
Stefan Oschmann Chairman
Iris Löw-Friedrich Chief Medical Officer & EVP-Development
Dhavalkumar Patel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
UCB9.26%20 457
CSL LIMITED9.25%102 521
WUXI BIOLOGICS (CAYMAN) INC.19.75%67 077
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 329
BIOGEN INC.22.60%44 738
ALEXION PHARMACEUTICALS, INC.0.00%40 336